Jet. Hope you are doing well. Thank you for all of your excellent DD and contributions to this board. I always look forward to your posts. For anyone out there that questions his genuine analysis, I will back him 100%. He has always prefaced his posts with speculation and risk, as all bio techs are vulnerable to a variety of risks. However, I am here as a long due to 3 potential compounds and a preclinical pipeline as well. Jet, if you could elaborate on the value of the discovery platform (as this is outside my league), I would appreciate it. Take care my friend....KGR
We have a highly productive discovery platform that continues to yield a portfolio rich in potential first-in-class and best-in-class compounds. Our discovery platform features small signaling molecule discovery (TIMES), computational predictive modeling (3D-GOLD) and nanoscale drug targeting and delivery. Working in concert, these technologies enables us to screen, select and optimize large numbers of compounds while retaining stringent selection criteria.
TIMES Platform (The Inhibitors of Multi-Expression Signals)
A discovery platform of small molecule inhibitors of multiple signaling molecules
In treating cancers, the combinational use of multiple cytotoxic drugs significantly increases the types and severity of harmful adverse reactions that patients experience. To address this issue, we utilize compound screening technology to streamline the drug discovery process prior to laboratory experimentation. Rexahn’s proprietary TIMES small molecule signaling technology has enabled us to discover more than a dozen targets involved in cancer proliferation. Using TIMES, we can more efficiently develop compounds with significantly increased efficacy and decreased undesirable side-effects.
3D-GOLD Platform (3D-Gateway Of Ligand Discovery)
A discovery tool of computational predictive molecular modeling
3D-GOLD is an integrated computational modeling tool of 3D-finger printing/pharmacophore, 3D-QSAR/proprietary QCID, 3D-ligand constructs, and 3D-dockings, that helps to predict the structural activity relationship of molecules using 3-dimensional models. 3D-GOLD is actively working to help Rexahn discover novel lead compounds. Leveraging this system, we are able to more effectively develop predictive models, formulate and test hypotheses for optimizing efficacy and increasing drug safety and bioavailability early in the process of drug discovery.
For more details, please refer to the QSID scientific article (Park DS, Kim JM, Lee YB, Ahn CH. QSID Tool: A new three-dimensional QSAR environmental tool. J Comput Aided Mol Des. 2008).
Nanoscale drug targeting and delivery
Development of innovative nanomedicines with higher efficacy and lower toxicity
In collaboration with nano-technology leaders, Rexahn is developing cutting-edge drug delivery systems that could increase bio-availability while minimizing adverse reactions. These technologies are based on nano-liposome and polymer encapsulation of existing medicines, an effective strategy to prolong drug action among other benefits.
dozens of new kids receive(d) and will continue to receive ETEP over the past few months and over the next few months, and there is obvious recognizable improvement, you will see 20 Christine's knocking on the FDA door. The parents testimonials (as conceded as an important FDA consideration), will trump this debacle dystrophin data, back into the pits of the labs, where they are being arrogantly scrutinized by a group with no idea of a true "Bulls Eye" methodology for reproducibility and validity. Even at that, SRPT's dystrophin analysis and assessments are as good, or better, than any comparator/competitor out there. Ten more mom's witnessing any form of early efficacy response, along with the safety study confirming minimal side effects, will make this dystrophin dynamic, a dramatically diminished Data point.
LOL I will pray for you my Beloved Pearsby, but it will not be for your business endeavors, rather for your mental health. And if you are truly married, an enormous and special prayer for your wife!
I have stated that I believe the NDA, in it fullest robustness can be submitted by June 30th (best case scenario, admittedly) I was challenged by other message boarders that that expectation is overly aggressive and unrealistic. Some are saying August 30th and even September 30th, as I suppose they marginally fall into mid June time frame. Best case scenario, June 30th or before, shorts get butchered, massacred, annihilated and the "Buying in" goes ballistic. Worst case scenario, Sept.30th, at current prices, that data and even allowable submission is 80% baked into the 12 dollar pps. Meaning, buying against this conviction creates for a huge upside with longer term patience (weeks/Months). Consider their IP, Cash and ongoing trials when looking at the pps. Finally, and to me most importantly, when Sept 30th arrives, I firmly believe there will not just be two or three overly zealous mothers in the FDA's face (FDA's Perspective..sadly) but perhaps, 20 or 30. Every additional day, week and month these kids have Etep in their systems, means more time for proven safety and unprecedented early efficacy responders. NOT measured by graphs and surrogates, but by family, friends and SELF. Good luck to the families, SRPT, investors who believe, ETEP and good ridden to shorts and malicious, unproven competitors. Also, may the FDA, expeditiously see the light! Less
Excuse my ignorance, but Phase 1 trials are usually designed to demonstrate safety only. I thought this has already been established, since we are in Phase 2 with other cancers. Seems safety and lesion size (efficacy could have been incorporated with the new tumors i.e. Phase 1/2 if you will. Do you know if they are looking at tumor size, pre and post treatment. Obviously not OS type end points, but something that shows a reason to advance into P2, with many of the cancers you have sited below.
A CEO who deceived with an A-7 steak sauce is receiving his punishment. Perhaps you newbies have an affinity for platform to platform successive failures and salary/dilution survival. Have at it!!
You have to have strong faith in getting your money and interest back....no matter what the interest rate or ROI. If the company fails, the 16% means nothing and you may not even get all of your cost basis back. If you were to loan money to a friend, and due to consequences, the friend pleaded his case that you will get your money back, as well as interest....He better be a quality, trustworthy and credible friend. There are many friends I would never loan to, and others that fit this scenario, if the circumstances dictate. IMSC has earned faith and trust to deliver. Albeit, not as swift as we would like, the extension is a sign of confidence.
Sorry. They have not validated even one indication or use as of yet. They have ONE product that has not been proven. That is why it remains at .38 cents and NO partnerships. A true pipeline means several different products and platforms. Just keep it real. This is a one shot speculative play....Period.
No deception here. I am long and holding. The bashturds will love this post. How about some communication? McGougewan, are new CEO, has not even addressed us in a formal introduction SHL with future insight to forward looking catalysts and strategy. How about anything? Go for it pumpers and Bashturds. Actually, I will be more receptive to the bashturds, unless a Pumpturd has something of substantive significance. Not something we already know...like TSA, Russia and China. There are no sales reported from the last 4 months. Both sides are idiots, and yes, I will admit I am stuck in the middle.
I am reposting this to reinforce the reason behind the consistent rebound when attacked by MM activity. Many investors want in LONG. However, there is little supply for them to accumulate under normal trading, so they are trying to take out vulnerable stop losses. I have been investing in Biotech and Medical device stocks for many years, this is a chance of a life time. If reading this board compromises your confidence in a long term hold, then do not spend an inordinate amount of time here. All the bashing is not short directed, but accumulation directed. Hold your treasure!
Cut the Pumping Pom Pom Jargon. Our new CEO has not even formally introduced himself as the new leader of this company. The volume is pathetic and there has been no disclosure of sales outside the TSA. The reason there is no volume and a manipulated pps, is management has duct taped themselves to their offices and are irresponsibly not communicating with their shareholders who are paying their salaries.
Though I am long IMSC and we can all bash Morpho. IMSC is languishing at .85 cents. It is time to talk about what IMSC is DOING, rather than talking about what Morpho cannot do.
Keep in mind the Float is roughly 17 million. That is almost unheard of for an early stage device company already producing sales and on a major exchange. This low float will ultimately be our friend long term, however, during the interim, will obviously create easy MM activity and volatility. Think long term with the potential of this company accompanied by a low float. The supply will never keep up with the eventual demand.
Overall Market taking a beating, CTSO up! Bashers Galore to no prevail. Next week will be robust with the foundation of the up list. This is a hold for the long term.